OBJECTIVE: There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. METHOD:Sixty participants in a double blind trial of olanzapine as a treatment for putative prodromal states were assessed at entry (pre-randomization), and again at 6 and 12 months (if they remained non-psychotic), or at any of these points prior to psychosis followed by post-psychosis and 6 months post-psychosis assessments. RESULTS:Participants who converted to psychosis did not differ from placebo non-converters in pre-randomization global neuropsychological status. Early converters did not differ from later converters in entry neuropsychological status. Subjects who converted after 6 months did not show neuropsychological declines during the initial, pre-psychosis, 6 months. Neuropsychological course did not differ between converters to psychosis and non-converters, or between olanzapine and placebo-assigned subjects. CONCLUSIONS: Neither the onset of frank psychosis nor olanzapine treatment of the prodrome significantly alters neuropsychological course in persons considered to be at high risk at their initial (pre-psychosis) assessment. These findings suggest that the neuropsychological deficiencies associated with psychotic conditions largely pre-exist the first frank psychotic episode.
RCT Entities:
OBJECTIVE: There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. METHOD: Sixty participants in a double blind trial of olanzapine as a treatment for putative prodromal states were assessed at entry (pre-randomization), and again at 6 and 12 months (if they remained non-psychotic), or at any of these points prior to psychosis followed by post-psychosis and 6 months post-psychosis assessments. RESULTS:Participants who converted to psychosis did not differ from placebo non-converters in pre-randomization global neuropsychological status. Early converters did not differ from later converters in entry neuropsychological status. Subjects who converted after 6 months did not show neuropsychological declines during the initial, pre-psychosis, 6 months. Neuropsychological course did not differ between converters to psychosis and non-converters, or between olanzapine and placebo-assigned subjects. CONCLUSIONS: Neither the onset of frank psychosis nor olanzapine treatment of the prodrome significantly alters neuropsychological course in persons considered to be at high risk at their initial (pre-psychosis) assessment. These findings suggest that the neuropsychological deficiencies associated with psychotic conditions largely pre-exist the first frank psychotic episode.
Authors: Larry J Seidman; Anthony J Giuliano; Eric C Meyer; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Bruce K Christensen; Keith Hawkins; Robert Heaton; Richard S E Keefe; Robert Heinssen; Barbara A Cornblatt Journal: Arch Gen Psychiatry Date: 2010-06
Authors: Lama M Chahine; Daniel Weintraub; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings Journal: Mov Disord Date: 2015-08-21 Impact factor: 10.338
Authors: P Fusar-Poli; M R Broome; P Matthiasson; J B Woolley; A Mechelli; L C Johns; P Tabraham; E Bramon; L Valmaggia; S C Williams; P McGuire Journal: Schizophr Bull Date: 2009-08-07 Impact factor: 9.306
Authors: S R Sponheim; R E Jung; L J Seidman; R I Mesholam-Gately; D S Manoach; D S O'Leary; B C Ho; N C Andreasen; J Lauriello; S C Schulz Journal: J Psychiatr Res Date: 2009-10-29 Impact factor: 4.791
Authors: Kristen A Woodberry; William R McFarlane; Anthony J Giuliano; Mary B Verdi; William L Cook; Stephen V Faraone; Larry J Seidman Journal: Schizophr Res Date: 2013-02-22 Impact factor: 4.939
Authors: Jimmy Choi; Cheryl M Corcoran; Joanna M Fiszdon; Michael Stevens; Daniel C Javitt; Melissa Deasy; Lawrence C Haber; Michael J Dewberry; Godfrey D Pearlson Journal: Psychiatr Rehabil J Date: 2016-08-25